The European Antibody Congress began in 2004 in Lille with a modest attendance of 120 people. The focus was to explore the discovery and development of new monoclonal antibodies (mAbs) for therapeutic purposes and to bring scientists together to share their ideas.
The conference was a huge success and quickly became the key event for updates on critical scientific advances in the antibody field with key players from pharma, biotech and CMOs in attendance. After moving to Geneva in 2010 and expanding the programme to include tracks on ADCs, Bispecifics and alternative protein scaffolds it was then joined by the World Biosimilar Congress in 2013 and in 2014 by the High Potency API congress to include over 400 delegates across all collocated conferences.
2015 heralded a move to the city of Basel, a major life science hub, home to major pharma and biotech companies such as Pfizer, Novartis & Roche and a site of global drug innovation.
The European Antibody Congress 2016 will introduce a innovation zone to provide opportunity for the SMEs to get in front of key pharma, biotech and investors from the Antibody industry. 2016 will also see an increased focus on Immunotherpy as we look to welcome over 500 attendees to the European Antibody Congress 2016 and the co-located World Biosimilar Congress 2016 and HPAPI World Congress 2016.